MiNK Therapeutics Files 8-K
Ticker: INKT · Form: 8-K · Filed: Mar 18, 2025 · CIK: 1840229
| Field | Detail |
|---|---|
| Company | Mink Therapeutics, Inc. (INKT) |
| Form Type | 8-K |
| Filed Date | Mar 18, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, legal
TL;DR
MiNK Therapeutics (fka AgenTus) updated its corporate info on 3/18/25.
AI Summary
On March 18, 2025, MiNK Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 149 Fifth Avenue, Suite 500, New York, NY 10010. The company was formerly known as AgenTus Therapeutics, Inc. until a name change on January 12, 2021.
Why It Matters
This 8-K filing provides updated corporate information for MiNK Therapeutics, Inc., including its current address and former company name, which is important for tracking corporate changes and maintaining accurate records.
Risk Assessment
Risk Level: low — This filing is a routine corporate update and does not contain information about financial performance, material events, or significant business changes.
Key Players & Entities
- MiNK Therapeutics, Inc. (company) — Registrant
- AgenTus Therapeutics, Inc. (company) — Former company name
- March 18, 2025 (date) — Date of report
- January 12, 2021 (date) — Date of name change
- 149 Fifth Avenue, Suite 500, New York, NY 10010 (address) — Principal Executive Offices
FAQ
What is the current name of the registrant?
The current name of the registrant is MiNK Therapeutics, Inc.
What was the former name of MiNK Therapeutics, Inc.?
The former name of MiNK Therapeutics, Inc. was AgenTus Therapeutics, Inc.
When did the company change its name?
The company changed its name on January 12, 2021.
What is the principal executive office address?
The principal executive office address is 149 Fifth Avenue, Suite 500, New York, NY 10010.
What is the date of this 8-K filing?
The date of this 8-K filing is March 18, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 18, 2025 regarding MiNK Therapeutics, Inc. (INKT).